Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
PTGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.22 - $60.60
Previous CloseN/A
Volume120.35K
Average Volume (3M)1.53M
Market Cap
$2.65B
Enterprise Value$2.16B
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)9.9
Beta1.03
Next Earnings
Apr 30, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding61,384,290
10 Day Avg. Volume1,140,453
30 Day Avg. Volume1,530,673
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.44
Price to Cash Flow (P/CF)-27.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda8.46
Forecast
1Y Price Target
$67.80Price Target Upside59.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe clinical success of icotrokinra and rusfertide bode well for additional programs from the oral peptide technology platform to support the company's long-term growth.
Financial StrengthThe $25M milestone payment on positive data will further strengthen the balance sheet to support a runway through at least year-end 2028 based on management's guidance.
Strong EfficacyIcotrokinra's UC data are seen as potentially transformative, with expectations of remission and response rates to persist in Ph3 studies.
Bears Say
Adverse EventsSafety profile is consistent with prior data with most adverse events being grade 1-2 injection site reactions and all serious adverse events deemed not drug related, with no increased cancer risks.
Dependency On Clinical StudiesThe next step will likely be a Phase 3 registrational study for icotrokinra in ulcerative colitis, with strong clinical data supporting further development in Crohn's disease.
Market CompetitionJNJ's announced decision to initiate a H2H study to show superiority of JNJ-2113 to ustekinumab (Stelara) in PsO suggests strong confidence in JNJ-2113's efficacy.
---
Ownership Overview
1.78% Insiders
16.13% Mutual Funds
0.17% Other Institutional Investors
53.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $24.22 and its highest was $60.60 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $2.65B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 20 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Feb 21, 2025. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.592.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 61,384,290 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of $1.98 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 0.676%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
---
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.80 (59.27% Upside)
$67.80 (59.27% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 81.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.34%
12-Months-Change
Fundamentals
Return on Equity
54.39%
Trailing 12-Months
Asset Growth
108.51%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
---
PTGX Stock 12 Month Forecast
Average Price Target
$67.80
▲(59.27% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Merus
―
Crispr Therapeutics AG
―
Scholar Rock Holding
―
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
20/21 ratings generated profit
1 Year Average Return
+69.90%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +69.90% per trade.
---